

**Harry Shamoan, M.D.***Associate Dean, Clinical and Translational Research, Einstein**Director, Einstein-Montefiore Institute for Clinical & Translational Research**Professor, Medicine (Endocrinology), Einstein**Attending Physician, Medicine, Montefiore Medical Center*

Harry Shamoan, M.D., has been a faculty member in Einstein's Diabetes Center and its department of medicine since completing his fellowship in endocrinology at Yale in 1979. His laboratory has studied the mechanisms of and treatment for defective counterregulation of hypoglycemia in people with type 1 diabetes, and established the link between frequent mild episodes of hypoglycemia and development of defective epinephrine secretion. He and colleagues also established the link between reduced epinephrine and glucagon secretion and impaired hepatic glucose production in hypoglycemia. Further studies elucidated the stimulus-specificity of the counterregulatory system; the role of hepatic "autoregulation" during hypoglycemia; and the function of glucokinase activation and other signaling systems in correcting or preventing impaired counterregulation. His lab also established the contributions of hepatic glycogen metabolism and gluconeogenesis during hypoglycemia.

Dr. Shamoan has directed major NIH-funded clinical trials such as the Diabetes Control and Complications Trial, the landmark study that established the benefits of intensive glycemic control in type 1 diabetes, and the Diabetes Prevention Program, which demonstrated the effects of lifestyle modification and metformin to prevent type 2 diabetes. Dr. Shamoan has been elected to the American Society of Clinical Investigation and the American Association of Physicians. He is associate dean for clinical and translational research, an attending physician at Montefiore Medical Center and director of the Einstein-Montefiore Institute for Clinical and Translational Research. He is also a member of the Clinical and Translational Science Award Consortium.